Balaxi Pharmaceuticals Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Balaxi Pharmaceuticals Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $253.2K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Balaxi Pharmaceuticals Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $253.2K Trade | TransData Nexus

Balaxi Pharmaceuticals Limited

Indian Pharmaceutical Exporter · Gastrointestinal Specialist · $253.2K Total Trade · DGFT Verified

Balaxi Pharmaceuticals Limited is an Indian pharmaceutical exporter with a total trade value of $253.2K across 2 products in 2 therapeutic categories. Based on 26 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Ranitidine ($171.1K), Captopril ($82.1K), .

Balaxi Pharmaceuticals Limited — Export Portfolio & Destination Treemap

Balaxi Pharmaceuticals Limited pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Balaxi Pharmaceuticals Limited? — Company Overview & Market Position

Balaxi Pharmaceuticals Limited, formerly known as Balaxi Ventures Limited, was incorporated on September 28, 1942, in Hyderabad, Telangana, India. The company underwent a name change in October 2020 to better reflect its focus on the pharmaceutical sector. As of March 13, 2026, Balaxi Pharmaceuticals is listed on the National Stock Exchange of India under the ticker symbol BALAXI, with a market capitalization of approximately ₹1.11 billion. The company operates with an authorized share capital of ₹400 million and a paid-up capital of ₹100 million. Balaxi Pharmaceuticals employs around 600 individuals, with a revenue of ₹2.76 billion in the trailing twelve months ending December 31, 2025. The company's registered office is located at Plot No. 409, H. No. 8-2-293, Maps Towers 3rd Floor, Phase-III, Road No. 81, Jubilee Hills, Hyderabad, Telangana 500096, India.

What Does Balaxi Pharmaceuticals Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Ranitidine$171.1K 2Captopril

Product Portfolio — Top 2 by Export Value

Balaxi Pharmaceuticals Limited exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ranitidine	Gastrointestinal	$171.1K	13	1.4%	15
2	Captopril	Cardiovascular	$82.1K	13	0.7%	12

Balaxi Pharmaceuticals Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $253.2K. The top category is Gastrointestinal (67.6% of portfolio), followed by Cardiovascular (32.4%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Balaxi Pharmaceuticals Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Balaxi Pharmaceuticals Limited sources its pharmaceutical formulations and builders' hardware products from contract manufacturers based in India, China, and Portugal. The company operates through an international wholesale trading model, leveraging its extensive distribution network to supply products across various regions. Specific details regarding the manufacturing plant locations, capacities, and specializations are not publicly disclosed.

3Key Leadership

The leadership team at Balaxi Pharmaceuticals Limited includes:

Ashish Maheshwari: Managing Director and Executive Chairman since 2020.

Kunal Mahendra Bhakta: Independent Non-Executive Director since 2017.

Minoshi Maheshwari: Non-Executive Director since 2017.

Gandhi Gamji: Independent Non-Executive Director since 2017.

Mangina Srinivas Rao: Independent Non-Executive Director since 2020.

Akshita Surana: Non-Executive Independent Director since 2024.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Balaxi Pharmaceuticals Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Balaxi Pharmaceuticals Limited has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company supplies pharmaceutical formulations and builders' hardware products through its international wholesale trading model, leveraging its distribution network to access these markets. Specific details regarding regulatory filings, approvals, and market access status in these regions are not publicly disclosed.

2Emerging Markets

Balaxi Pharmaceuticals Limited has expanded its footprint into emerging markets such as Africa, Latin America, and Southeast Asia. The company has secured 548 product registrations across multiple therapeutic segments, facilitating its entry into these regions. Additionally, Balaxi Pharmaceuticals has established a branded FMCG business, complementing its pharmaceutical operations and providing operating leverage through well-established on-ground infrastructure and channel relationships.

3Geographic Strategy

Balaxi Pharmaceuticals Limited's geographic strategy involves diversification into frontier markets, including regions in Africa, Latin America, and Southeast Asia. The company's focus on securing product registrations and establishing distribution networks in these areas indicates a strategic direction aimed at reducing concentration risk and tapping into high-growth markets. This approach aligns with Balaxi Pharmaceuticals' mission to expand into 20 frontier markets over the next five years. (balaxipharma.do)

Balaxi Pharmaceuticals Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Balaxi Pharmaceuticals Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed. The company's international wholesale trading model suggests that it may not have direct manufacturing facilities registered with the FDA. However, Balaxi Pharmaceuticals sources its pharmaceutical formulations from contract manufacturers based in India, China, and Portugal, which may hold the necessary FDA approvals for their products.

2WHO & EU GMP

Balaxi Pharmaceuticals Limited sources its pharmaceutical formulations from contract manufacturers based in India, China, and Portugal. The company emphasizes that its products are procured from WHO GMP certified contract manufacturers, ensuring compliance with international quality standards. Specific details regarding WHO prequalification, EU GMP certificates, and EDQM status are not publicly disclosed.

3CDSCO & Indian Regulatory

Balaxi Pharmaceuticals Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Balaxi Pharmaceuticals Limited operates in a competitive landscape, supplying pharmaceutical formulations and builders' hardware products through its international wholesale trading model. The company's focus on frontier markets, including regions in Africa, Latin America, and Southeast Asia, positions it against both local and international competitors aiming to establish a presence in these high-growth areas. Specific market share comparisons and head-to-head analyses are not publicly available.

2Key Differentiators

Balaxi Pharmaceuticals Limited differentiates itself through its extensive product portfolio, comprising 548 registrations across multiple therapeutic segments. The company's international wholesale trading model, combined with its branded FMCG business, provides operating leverage and complements its pharmaceutical operations. Additionally, Balaxi Pharmaceuticals' focus on frontier markets and its mission to expand into 20 such markets over the next five years demonstrate a strategic approach to growth and market diversification. (balaxipharma.do)

3Strategic Position

Buyer Due Diligence Brief — Evaluating Balaxi Pharmaceuticals Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Balaxi Pharmaceuticals Limited sources its pharmaceutical formulations from contract manufacturers based in India, China, and Portugal. The company emphasizes that its products are procured from WHO GMP certified contract manufacturers, ensuring compliance with international quality standards. Specific details regarding the overall track record, export volume, consistency, and reliability indicators of these suppliers are not publicly disclosed.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Approval: Confirm that the product is listed in the FDA's Orange Book or that the manufacturing facility is registered with the FDA.

WHO GMP Certification: Ensure that the manufacturing facility holds a valid WHO GMP certificate.

EU GMP Certification: Verify that the manufacturing facility is certified under EU GMP standards.

Frequently Asked Questions — Balaxi Pharmaceuticals Limited

How many pharmaceutical products does Balaxi Pharmaceuticals Limited export from India?

Balaxi Pharmaceuticals Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Ranitidine ($171.1K), Captopril ($82.1K). Total export value is $253.2K.

What is Balaxi Pharmaceuticals Limited's total pharmaceutical export value?

Balaxi Pharmaceuticals Limited's total pharmaceutical export value is $253.2K, based on 26 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Balaxi Pharmaceuticals Limited cover?

Balaxi Pharmaceuticals Limited exports across 2 therapeutic categories. The largest are Gastrointestinal (67.6%, 1 products), Cardiovascular (32.4%, 1 products).

Get Full Balaxi Pharmaceuticals Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.